A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
What is the purpose of this trial?
This study will evaluate the safety and efficacy of ARV-766 in men with metastatic castration-resistant prostate cancer.
- Trial withArvinas, Inc.
- Start Date05/23/2022
- End Date01/01/2100
- Last Updated09/28/2022
- Study HIC#2000030751